ReviewCurrent hypertension reports2015
Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders.
Review in Current hypertension reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The impact of statins on aldosterone production in healthy adults: a randomized controlled study.Journal of the Endocrine Society · 2026Article
- Understanding the Role of Adipokines in Cardiometabolic Dysfunction: A Review of Current Knowledge.Biomolecules · 2025Review
- Molecular Insight into Obesity-Associated Nephropathy: Clinical Implications and Possible Strategies for its Management.Current drug targets · 2025Review
- Primary Aldosteronism and Resistant Hypertension: A Pathophysiological Insight.International journal of molecular sciences · 2022Review
- Kidney Damage Caused by Obesity and Its Feasible Treatment Drugs.International journal of molecular sciences · 2022Review
- New Pandemic: Obesity and Associated Nephropathy.Frontiers in medicine · 2021Review
- A clinical trial to evaluate the effect of statin use on lowering aldosterone levels.BMC endocrine disorders · 2020Article
- Article
- Eplerenone Implantation Improved Adipose Dysfunction Averting RAAS Activation and Cell Division.Frontiers in endocrinology · 2020Article
- Heart Failure in Type 2 Diabetes Mellitus.Circulation research · 2019Review
- Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome.Current hypertension reports · 2018Review
- Article
- Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis.Nature reviews. Nephrology · 2016Review
- Endothelial Mineralocorticoid Receptor Deletion Prevents Diet-Induced Cardiac Diastolic Dysfunction in Females.Hypertension (Dallas, Tex. : 1979) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Preclinical studies have convincingly demonstrated a role for the mineralocorticoid receptor (MR) in adipose tissue physiology. These studies show that increased MR activation causes adipocyte dysfunction leading to decreased production of insulin-sensitizing products and increased production of inflammatory factors, creating an environment conducive to metabolic and cardiovascular disease. Accumulating data also suggest that MR activation may be an important link between obesity and metabolic syndrome. Moreover, MR activation may mediate the pathogenic consequences of metabolic syndrome. Recent attempts at reversing cardiometabolic damage in patients with type 2 diabetes using MR antagonists have shown promising results. MR antagonists are already used to treat heart failure where their use decreases mortality and morbidity over and above the use of traditional therapies alone. However, more data are needed to establish the benefits of MR antagonists in diabetes, obesity, and metabolic syndrome.
Indexed as
Identifiers
26068659What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.